Valsartan, Losartan & Irbesartan Lawsuit
Blood Pressure Medication Contamination
Plaintiffs allege that generic blood pressure medications containing valsartan, losartan, and irbesartan were contaminated with nitrosamine impurities (NDMA, NDEA, NMBA) traced to manufacturing process changes at overseas API suppliers. With 1,418 pending actions and bellwether trial preparation ongoing, this MDL remains one of the most significant pharmaceutical contamination cases in the federal court system.
Key Takeaways
- Over 1,400 cases pending alleging NDMA/NDEA contamination in blood pressure medications
- Contamination traced to manufacturing process changes at Chinese/Indian API suppliers (Zhejiang Huahai)
- FDA issued dozens of recalls from July 2018 through 2019, affecting millions of patients worldwide
- NDMA and NDEA classified as Group 2A probable human carcinogens by IARC
- No settlements or jury verdicts reported — bellwether trial preparation ongoing
May 2026 Updates Latest
MDL has 1,424 pending actions out of 2,428 total per the May 2026 JPML statistics report. With the June 2, 2026 claim deadline now four weeks away, claims administrators are processing a final wave of submissions for the combined $15.26 million economic-loss settlement covering Hetero ($11.37M), Aurobindo ($2M), and Vivimed ($1.9M) — resolving overpayment claims by consumers and insurers for contaminated valsartan, losartan, and irbesartan.
The final approval hearing is set for June 30, 2026 before Judge Kugler in Courtroom 3D of the District of New Jersey, where any remaining objections will be heard before disbursement of the qualified settlement funds. The economic-loss class settlements do not release personal injury or medical monitoring claims, and Wave 2 bellwether trial preparation against Zhejiang Huahai (ZHP) continues through expert discovery, with trial dates anticipated in late 2026 once Daubert challenges are resolved.
Key Facts (May 2026)
| Pending Actions | 1,424+ cases in federal MDL |
| Total Actions Filed | 1,615+ cases |
| Key Defendants | Zhejiang Huahai, Hetero Labs, Aurobindo Pharma, generic manufacturers |
| Presiding Judge | Chief Judge Renee M. Bumb (D.N.J.) |
| MDL Created | February 14, 2019 (transferred by JPML) |
| Alleged Injuries | Liver, stomach, colorectal, kidney, pancreatic cancer |
| Contaminants | NDMA, NDEA, NMBA — nitrosamine impurities |
| Can You Still File? | Open — limited (consult attorney for eligibility) |
Steady Case Growth
Valsartan MDL filings have grown steadily since the MDL was created in February 2019. Case count has increased over 4,500% from 30 initial cases to 1,424 pending actions as bellwether trial preparation drives continued filing activity.
Source: JPML MDL Statistics Reports, February 2019–May 2026
1 What Is This Lawsuit About?
MDL-2875 consolidates lawsuits from patients who took generic blood pressure medications containing valsartan, losartan, or irbesartan and were later diagnosed with cancer. Plaintiffs allege that these medications were contaminated with nitrosamine impurities — specifically NDMA and NDEA — which are classified as probable human carcinogens.
The contamination was traced to manufacturing process changes at overseas active pharmaceutical ingredient (API) suppliers, primarily Zhejiang Huahai Pharmaceutical in China. Patients allege they were unknowingly exposed to carcinogenic impurities for years through their daily blood pressure medication.
2 What Are ARBs (Valsartan, Losartan, Irbesartan)?
Angiotensin II receptor blockers (ARBs) are a class of medications prescribed to treat high blood pressure (hypertension), heart failure, and kidney disease. They work by blocking the action of angiotensin II, a hormone that narrows blood vessels, thereby lowering blood pressure and reducing strain on the heart.
ARBs are among the most widely prescribed medications in the United States, with over 100 million prescriptions filled annually. Valsartan, losartan, and irbesartan — the three drugs at issue in this MDL — share a common chemical feature known as a tetrazole ring structure, which is relevant to the contamination mechanism.
Valsartan
Brand name Diovan (Novartis). First approved 1996. Used for hypertension, heart failure, and post-heart attack care.
Losartan
Brand name Cozaar (Merck). First ARB approved in 1995. Also treats diabetic nephropathy and stroke prevention.
Irbesartan
Brand name Avapro (Sanofi/BMS). Approved 1997. Prescribed for hypertension and diabetic nephropathy.
3 The Contamination Crisis (NDMA/NDEA)
Nitrosamines are a class of chemical compounds classified by the International Agency for Research on Cancer (IARC) as Group 2A probable human carcinogens. NDMA (N-nitrosodimethylamine) and NDEA (N-nitrosodiethylamine) have been shown to cause cancer in laboratory animals and are considered likely to cause cancer in humans at sufficient exposure levels.
The contamination was discovered in June-July 2018 when the European Medicines Agency (EMA) was alerted to the presence of NDMA in valsartan products supplied by Zhejiang Huahai Pharmaceutical (ZHP) in China. Investigation revealed that ZHP had changed its manufacturing process around 2012, inadvertently introducing a chemical reaction that generated NDMA as a byproduct — meaning patients may have been exposed for four or more years before the contamination was detected.
How Did the Contamination Happen?
API suppliers changed their synthesis process for valsartan, introducing new solvents and reagents to improve yield and reduce costs.
The modified process created conditions for nitrosamine formation — the combination of certain amines with nitrite reagents produced NDMA and NDEA as unwanted byproducts.
Standard quality control testing at the time did not screen for nitrosamine impurities, so the contamination went undetected for years.
Multiple API suppliers using similar processes were eventually found to have contamination issues, expanding the scope beyond a single manufacturer.
4 FDA Recalls & Regulatory Response
The FDA issued dozens of recalls between 2018 and 2019 as the scope of contamination became clear. The recall timeline illustrates how the crisis expanded from valsartan to include losartan and irbesartan products.
FDA announces voluntary recalls of valsartan products containing NDMA traced to Zhejiang Huahai Pharmaceutical. Multiple generic manufacturers affected.
A second nitrosamine impurity, NDEA, is found in valsartan products. FDA places Zhejiang Huahai on import alert, blocking all API shipments to the U.S.
Contamination expands beyond valsartan. Irbesartan products recalled after NDEA detected in API from separate suppliers.
Losartan products recalled. FDA establishes acceptable daily intake limits for NDMA (96 ng/day) and NDEA (26.5 ng/day) in ARB medications.
A third nitrosamine impurity, NMBA (N-nitroso-N-methyl-4-aminobutyric acid), is discovered. Recalls continue to expand across manufacturers and products.
FDA Risk Assessment & Patient Guidance
The FDA estimated that exposure to the NDMA levels found in contaminated valsartan could result in approximately 1 additional case of cancer per 8,000 patients treated over a four-year period at worst-case contamination levels.
Following the ARB contamination crisis, the FDA launched a broader nitrosamine impurity initiative requiring all pharmaceutical manufacturers to evaluate and test their products for nitrosamine contamination — a program that subsequently identified nitrosamines in ranitidine, metformin, and other widely-used medications.
5 Alleged Health Effects & Scientific Evidence
Plaintiffs allege that long-term exposure to nitrosamine-contaminated ARBs caused various types of cancer. The scientific basis rests on NDMA and NDEA's classification as probable carcinogens by the International Agency for Research on Cancer (IARC).
Cancer Types Alleged in Litigation
The liver is particularly relevant because NDMA is metabolized hepatically, where it undergoes bioactivation to form DNA-reactive methyldiazonium ions that can cause mutagenic damage.
Scientific Basis
- • IARC Group 2A classification (probable human carcinogen)
- • Animal studies show liver tumors at high NDMA doses
- • NDMA causes DNA alkylation (damage to genetic material)
- • Chronic low-dose exposure is biologically plausible pathway
- • FDA confirmed contamination levels above acceptable limits
Causation Challenges
- • Long latency period between exposure and cancer diagnosis
- • Multiple confounding risk factors for alleged cancers
- • Difficulty proving individual-specific causation
- • Actual NDMA dose received varies by manufacturer and lot
- • Limited human epidemiological data specific to ARB contamination
6 MDL History & Current Status
The Judicial Panel on Multidistrict Litigation (JPML) created MDL-2875 on February 14, 2019, consolidating valsartan contamination cases in the District of New Jersey under Chief Judge Renee M. Bumb. The MDL was originally limited to valsartan products but was later expanded to include losartan and irbesartan claims as the scope of contamination broadened.
As of the March 2026 JPML statistics report, the MDL has 1,418 pending actions out of 1,607 total filed. The litigation is in an active pretrial phase with bellwether case preparation ongoing. Expert testimony and Daubert proceedings on general causation remain a central focus.
Key Litigation Timeline
7 Who May Qualify for a Claim?
- Took a recalled valsartan, losartan, or irbesartan product (generic version)
- Subsequently diagnosed with liver, stomach, colorectal, kidney, or pancreatic cancer
- Have pharmacy records documenting prescription history and medication manufacturer
Statute of Limitations: Time limits vary by state, typically 2-4 years from diagnosis or discovery of the connection to contaminated medication. Consult an attorney promptly to evaluate your specific situation.
8 Settlement Status
No global settlement or individual settlements have been publicly announced in MDL-2875 as of May 2026. There have been no jury verdicts. The litigation remains in an active pretrial phase.
The outcome of bellwether trials — the first cases selected for trial to test the strength of claims — will likely be the primary driver of any future settlement negotiations. If plaintiffs can successfully establish general causation (that nitrosamine-contaminated ARBs can cause cancer), defendants may face significant pressure to negotiate a global resolution.
Current Litigation Posture
Bellwether trial outcomes will likely be the key factor in determining whether settlement negotiations begin in earnest. The complex multi-defendant supply chain may result in varying settlement approaches for different defendant groups.
9 Key Defendants
This MDL involves a complex pharmaceutical supply chain spanning API suppliers, generic manufacturers, and brand-name companies. The defendants fall into three primary categories:
API Suppliers (Active Pharmaceutical Ingredient)
- Zhejiang Huahai Pharmaceutical (China)
Primary source of contaminated valsartan API. Manufacturing process change around 2012 introduced NDMA formation. Placed on FDA import alert in September 2018.
- Hetero Labs (India)
Indian API supplier found to have NDMA contamination in losartan products. Subject to FDA warning letters.
- Aurobindo Pharma (India)
Major Indian pharmaceutical company supplying valsartan and losartan API. Multiple lots recalled due to nitrosamine contamination.
Generic Manufacturers
- Teva Pharmaceutical / Actavis
Major generic manufacturer. Multiple valsartan and losartan products recalled.
- Mylan N.V.
Global generic manufacturer with recalled valsartan products sourced from affected API suppliers.
- Torrent Pharmaceuticals
Indian generic manufacturer. Among the first to issue valsartan recalls in July 2018.
- Sandoz (Novartis), Camber, others
Additional generic manufacturers affected by contaminated API supply chain.
Brand-Name Companies
Novartis (Diovan) — Original brand manufacturer of valsartan. Has a more limited role in the MDL because the contamination primarily affected generic versions of the drugs, not brand-name products manufactured by Novartis.
Note: The brand-name ARB products (Diovan, Cozaar, Avapro) were generally not subject to the same contamination because their API was sourced from different manufacturing processes than those used by the affected generic API suppliers.
Frequently Asked Questions
What are ARB medications?
Angiotensin II receptor blockers (ARBs) are a class of blood pressure medications that work by blocking the hormone angiotensin II, which normally causes blood vessels to narrow. By blocking this receptor, ARBs relax blood vessels and lower blood pressure. They are commonly prescribed for hypertension, heart failure, and kidney protection in diabetic patients. Valsartan, losartan, and irbesartan are three of the most widely prescribed ARBs.
Should I stop taking my blood pressure medication?
No — do not stop taking blood pressure medication without consulting your doctor. The FDA specifically advised patients to continue their prescribed ARB medication because the risk of uncontrolled hypertension (including stroke and heart attack) generally outweighs the potential cancer risk from contamination. Your doctor can switch you to a non-recalled product or alternative medication if needed.
How was the contamination discovered?
The contamination was discovered in mid-2018 when the European Medicines Agency (EMA) was alerted to the presence of NDMA in valsartan products from Zhejiang Huahai Pharmaceutical. Subsequent investigation revealed that a manufacturing process change around 2012 had introduced conditions for nitrosamine formation, meaning patients may have been exposed to contaminated products for up to six years before detection.
What types of cancer are alleged in the lawsuits?
Plaintiffs allege various cancer types including liver cancer, stomach (gastric) cancer, colorectal cancer, kidney cancer, and pancreatic cancer. These are the organs most commonly associated with nitrosamine exposure based on animal studies. The liver is particularly relevant because NDMA is metabolized in the liver, where it can cause DNA damage.
How do I know if my medication was contaminated?
The FDA maintains a complete list of recalled ARB products on its website, searchable by manufacturer, NDC (National Drug Code), and lot number. Check your prescription bottle for the manufacturer name and lot number, then cross-reference with the FDA recall list. Your pharmacy may also be able to confirm whether your specific medication was part of a recall.
Is there a settlement?
No. As of March 2026, there has been no global settlement, no publicly announced individual settlements, and no jury verdicts in MDL-2875. The litigation remains in an active pretrial phase with bellwether trial preparation ongoing. Settlement negotiations are expected to begin in earnest only after bellwether trial outcomes provide a clearer picture of case values.
Who qualifies to file a claim?
You may qualify if you: (1) took a recalled valsartan, losartan, or irbesartan product, (2) were subsequently diagnosed with cancer (particularly liver, stomach, colorectal, kidney, or pancreatic), and (3) have pharmacy records documenting your prescription history. Statute of limitations varies by state, so consult an attorney promptly to evaluate your specific situation.
Sources & References
11 official sources cited• JPML MDL Statistics Report, March 2026 (MDL-2875 pending/total actions)
• StatPearls, "Angiotensin II Receptor Blockers" (mechanism of action, pharmacology)
• AHA/ACC Guidelines for Management of High Blood Pressure (ARB prescribing)
• FDA Recalls, Market Withdrawals & Safety Alerts: Valsartan, Losartan, Irbesartan (2018-2019)
• European Medicines Agency (EMA) Referral: Angiotensin-II-receptor antagonists (sartan) containing a tetrazole group
• International Agency for Research on Cancer (IARC) Monographs on NDMA/NDEA (Group 2A)
• FDA Updates and Press Announcements on Angiotensin II Receptor Blocker Recalls
• FDA Nitrosamines Impurities Initiative: Control of Nitrosamine Impurities in Human Drugs
• JPML Transfer Order, MDL-2875 (February 14, 2019)
• U.S. District Court, District of New Jersey — MDL-2875 Official Docket
• GovInfo: Court Opinions and Orders, IN RE: Valsartan, Losartan, and Irbesartan Products Liability Litigation
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.